Impact of elexacaftor–tezacaftor–ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis

• Published in: Pediatric pulmonology Vol. 58; no. 3; pp. 825 - 833
• Main Authors: Sheikh, Shahid, Britt, Rodney D., Ryan‐Wenger, Nancy A., Khan, Aiman Q., Lewis, Brandon W., Gushue, Courtney, Ozuna, Hazel, Jaganathan, Devi, McCoy, Karen, Kopp, Benjamin T.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2023
• Subjects: Adolescent; Adult; Aminophenols - therapeutic use; Benzodioxoles - therapeutic use; Body mass index; CFTR; Cystic fibrosis; Cystic Fibrosis - complications; Cystic Fibrosis - drug therapy; Cystic Fibrosis - metabolism; Cystic Fibrosis Transmembrane Conductance Regulator - metabolism; Cytokines; Cytokines - metabolism; Female; Humans; infection; inflammation; Interleukin-17 - metabolism; Interleukin-17 - therapeutic use; Interleukin-8 - metabolism; Interleukin-8 - therapeutic use; Male; Mutation; Young Adult; infection; inflammation; cystic fibrosis; CFTR

Background Cystic fibrosis (CF) is a multisystem disease with progressive deterioration. Recently, CF transmembrane conductance regulator (CFTR) modulator therapies were introduced that repair underlying protein defects. Objective of this study was to determine the impact of elexacaftor–tezacaftor–i...